stoxline Quote Chart Rank Option Currency Glossary
Kiniksa Pharmaceuticals, Ltd. (KNSA)
16.95  -0.51 (-2.92%)    04-17 16:00
Open: 17.54
High: 17.57
Volume: 370,995
Pre. Close: 17.46
Low: 16.92
Market Cap: 1,197(M)
Technical analysis
2024-04-17 4:47:51 PM
Short term     
Mid term     
Targets 6-month :  22.63 1-year :  24.41
Resists First :  19.37 Second :  20.89
Pivot price 18.13
Supports First :  16.92 Second :  14.07
MAs MA(5) :  17.36 MA(20) :  18.57
MA(100) :  18.73 MA(250) :  16.86
MACD MACD :  -0.8 Signal :  -0.6
%K %D K(14,3) :  9.4 D(3) :  11.9
RSI RSI(14): 26.4
52-week High :  22.09 Low :  10.64
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ KNSA ] has closed above bottom band by 18.1%. Bollinger Bands are 52% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 17.59 - 17.68 17.68 - 17.76
Low: 16.7 - 16.81 16.81 - 16.9
Close: 16.78 - 16.96 16.96 - 17.1
Company Description

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Headline News

Tue, 16 Apr 2024
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024 - Yahoo Finance

Tue, 16 Apr 2024
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Short Interest Up 11.8% in March - Defense World

Tue, 16 Apr 2024
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Sees Large Growth in Short Interest - MarketBeat

Tue, 09 Apr 2024
Vanguard Group Inc. Sells 128255 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - Defense World

Fri, 05 Apr 2024
FY2027 EPS Estimates for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Decreased by Wedbush - Defense World

Tue, 02 Apr 2024
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 40 (M)
Shares Float 32 (M)
Held by Insiders 3.9 (%)
Held by Institutions 90.2 (%)
Shares Short 3,210 (K)
Shares Short P.Month 2,780 (K)
Stock Financials
EPS 0.2
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.23
Profit Margin 5.2 %
Operating Margin 0.1 %
Return on Assets (ttm) -3.2 %
Return on Equity (ttm) 3.3 %
Qtrly Rev. Growth 34.7 %
Gross Profit (p.s.) 0
Sales Per Share 6.75
EBITDA (p.s.) -0.58
Qtrly Earnings Growth 550 %
Operating Cash Flow 13 (M)
Levered Free Cash Flow 14 (M)
Stock Valuations
PE Ratio 84.75
PEG Ratio 1
Price to Book value 2.72
Price to Sales 2.5
Price to Cash Flow 50.95
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android